Sunday, June 11, 2017

Wednesday, June 14, 2017, 9:00 — 11:15 a.m. Fostering competition in the pharmaceutical distribution chain

What if cooperative ownership of pharmaceutical companies and distribution chain OWNED up to 60% would 
that make a difference globally in drug distribution and pricing?

Could community ownership make a difference in ensuring equal pricing and distribution for all?

June 11, 2017
A pharmacist counts pills in a pharmacy in Toronto in this January 31, 2008 file photo. Pressured by an aging population and the need to rein in budget deficits, Canada's provinces are taking tough measures to curb healthcare costs, a trend that could erode the principles of the popular state-funded system. To match ANALYSIS CANADA-HEALTH/ REUTERS/Mark Blinch/Files  (CANADA - Tags: HEALTH POLITICS BUSINESS) - RTR2ELV1

Fostering competition in the 

pharmaceutical distribution 


Wednesday, June 14, 2017, 9:00 to 11:15 a.m. EDT
On Wednesday, June 14, Brookings and USC will host 
a forum to explore the many segments of the drug 
distribution chain and examine proposals to reduce 
price markups through increased competition.

When: Wednesday, June 14, 2017, 9:00 — 11:15 a.m.
Where: The Brookings Institution, Falk Auditorium, 1775 Massachusetts Ave, NW, Washington, DC

Although a great deal of attention concerning prescription drug prices centers on the prices charged
by pharmaceutical manufacturers themselves, markups in the distribution chain—pharmacy
benefit managers, wholesalers, and pharmacies—are often substantial. Despite the large role that
these actors play, little is known about the discounts they negotiate or markups they charge and
how those relate to what patientsultimately pay.
On Wednesday, June 14, the USC-Brookings Schaeffer Initiative for Innovation in Health Policy
will host a forum to explore the many segments of the drug distribution chain and examine proposals
to reduce price markups through increased competition.
The event will feature a presentation of two new papers: one estimating profitability in the distribution
chains of both branded and generic drugs and another proposing a transparency scheme to foster
competition in the distribution of generic pharmaceuticals. Stakeholder panels will follow the presentations
of these two papers, to discuss approaches to increase competition in brand and generic drug distribution.
After the session, panelists will take audience questions.

No comments:

Post a Comment

Search This Blog

ARCHIVE List 2011 - Present